Wooridul Huebrain Limited (118000.KS)
KRW 295.0
(-1.99%)
KRW 295.0
(-1.99%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.52 Billion KRW | -61.33% |
| 2022 | 6.51 Billion KRW | 27.9% |
| 2021 | 5.09 Billion KRW | 106.92% |
| 2020 | 2.46 Billion KRW | -42.76% |
| 2019 | 4.3 Billion KRW | 119.45% |
| 2018 | 1.96 Billion KRW | -49.89% |
| 2017 | 3.91 Billion KRW | 692.34% |
| 2016 | -660.41 Million KRW | -171.67% |
| 2015 | 921.48 Million KRW | -70.07% |
| 2014 | 3.07 Billion KRW | 26.6% |
| 2013 | 2.43 Billion KRW | 3.9% |
| 2012 | 2.34 Billion KRW | -58.08% |
| 2011 | 5.58 Billion KRW | -4.43% |
| 2010 | 5.84 Billion KRW | 889.57% |
| 2009 | 590.37 Million KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.82 Billion KRW | 311.7% |
| 2024 Q2 | 1.31 Billion KRW | -0.23% |
| 2023 FY | 2.52 Billion KRW | -61.33% |
| 2023 Q2 | 1.04 Billion KRW | -54.45% |
| 2023 Q1 | 2.29 Billion KRW | 39.05% |
| 2023 Q4 | -860.91 Million KRW | -154.12% |
| 2023 Q3 | 1.59 Billion KRW | 51.98% |
| 2022 FY | 6.51 Billion KRW | 27.9% |
| 2022 Q2 | 1.74 Billion KRW | 10.0% |
| 2022 Q1 | 1.58 Billion KRW | -5.41% |
| 2022 Q3 | 1.53 Billion KRW | -12.02% |
| 2022 Q4 | 1.65 Billion KRW | 7.69% |
| 2021 Q3 | 1.5 Billion KRW | -9.59% |
| 2021 Q1 | 243.56 Million KRW | -41.41% |
| 2021 FY | 5.09 Billion KRW | 106.92% |
| 2021 Q2 | 1.66 Billion KRW | 584.74% |
| 2021 Q4 | 1.67 Billion KRW | 11.17% |
| 2020 Q4 | 415.72 Million KRW | -45.32% |
| 2020 Q2 | 588.26 Million KRW | -15.77% |
| 2020 Q1 | 698.36 Million KRW | -62.7% |
| 2020 FY | 2.46 Billion KRW | -42.76% |
| 2020 Q3 | 760.28 Million KRW | 29.24% |
| 2019 Q1 | 623.32 Million KRW | 163.2% |
| 2019 FY | 4.3 Billion KRW | 119.45% |
| 2019 Q3 | 975.63 Million KRW | 17.39% |
| 2019 Q4 | 1.87 Billion KRW | 91.89% |
| 2019 Q2 | 831.09 Million KRW | 33.33% |
| 2018 Q1 | 1.02 Billion KRW | -69.65% |
| 2018 Q4 | -986.34 Million KRW | -246.19% |
| 2018 Q3 | 674.71 Million KRW | -45.72% |
| 2018 FY | 1.96 Billion KRW | -49.89% |
| 2018 Q2 | 1.24 Billion KRW | 20.81% |
| 2017 FY | 3.91 Billion KRW | 692.34% |
| 2017 Q2 | 104.86 Million KRW | 155.35% |
| 2017 Q3 | 606.34 Million KRW | 478.2% |
| 2017 Q4 | 3.39 Billion KRW | 459.11% |
| 2017 Q1 | -189.45 Million KRW | 58.73% |
| 2016 Q1 | -93.75 Million KRW | -137.82% |
| 2016 FY | -660.41 Million KRW | -171.67% |
| 2016 Q4 | -459.06 Million KRW | -3248.87% |
| 2016 Q3 | -13.7 Million KRW | 85.4% |
| 2016 Q2 | -93.88 Million KRW | -0.14% |
| 2015 Q4 | 247.85 Million KRW | -31.42% |
| 2015 Q3 | 361.42 Million KRW | 224.16% |
| 2015 FY | 921.48 Million KRW | -70.07% |
| 2015 Q1 | 603.29 Million KRW | 43.78% |
| 2015 Q2 | -291.09 Million KRW | -148.25% |
| 2014 Q1 | 840.04 Million KRW | -13.5% |
| 2014 FY | 3.07 Billion KRW | 26.6% |
| 2014 Q4 | 419.6 Million KRW | -63.26% |
| 2014 Q3 | 1.14 Billion KRW | 68.74% |
| 2014 Q2 | 676.85 Million KRW | -19.43% |
| 2013 Q1 | 684.51 Million KRW | 61.21% |
| 2013 Q3 | 73.36 Million KRW | -89.56% |
| 2013 FY | 2.43 Billion KRW | 3.9% |
| 2013 Q2 | 702.84 Million KRW | 2.68% |
| 2013 Q4 | 971.1 Million KRW | 1223.59% |
| 2012 FY | 2.34 Billion KRW | -58.08% |
| 2012 Q2 | 64.81 Million KRW | -94.1% |
| 2012 Q1 | 1.09 Billion KRW | 323.62% |
| 2012 Q4 | 424.6 Million KRW | -43.51% |
| 2012 Q3 | 751.61 Million KRW | 1059.61% |
| 2011 Q2 | 1.87 Billion KRW | -5.42% |
| 2011 Q4 | 259.54 Million KRW | -82.3% |
| 2011 FY | 5.58 Billion KRW | -4.43% |
| 2011 Q1 | 1.98 Billion KRW | 46.38% |
| 2011 Q3 | 1.46 Billion KRW | -21.82% |
| 2010 Q3 | 1.77 Billion KRW | 32.7% |
| 2010 Q2 | 1.34 Billion KRW | -1.87% |
| 2010 Q1 | 1.36 Billion KRW | 0.0% |
| 2010 FY | 5.84 Billion KRW | 889.57% |
| 2010 Q4 | 1.35 Billion KRW | -23.89% |
| 2009 FY | 590.37 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Daewoong Co., Ltd. | 931.19 Billion KRW | 99.729% |
| PharmGen Science, Inc. | 96.19 Billion KRW | 97.38% |